Veracyte snaps up C2i Genomics, revolutionizing cancer care with $95M!
TLDR: Cancer diagnostics company Veracyte has acquired Israeli startup C2i Genomics for up to $95 million. C2i Genomics has developed a test platform using whole-genome tumor sequencing and has raised $112 million